Based on the Alterity Therapeutics Limited stock forecast from 0 analysts, the average analyst target price for Alterity Therapeutics Limited is not available over the next 12 months. Alterity Therapeutics Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Alterity Therapeutics Limited is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, Alterity Therapeutics Limited’s stock price was USD 0.0036. Alterity Therapeutics Limited’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -18.18% over the last year.
No recent analyst target price found for Alterity Therapeutics Limited
No recent average analyst rating found for Alterity Therapeutics Limited
Company Overview Alterity Therapeutics Limited
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. Read Less
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical...Read More
Frequently Asked Questions About Alterity Therapeutics Limited (PRNAF) Stock
Stock Target Advisor's fundamental analysis for Alterity Therapeutics Limited's stock is Slightly Bearish.
Unfortunately we do not have enough data on PRNAF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PRNAF's stock to indicate what its average analyst target is.
PRNAF stock's Price/Earning ratio is 0.10.
Our analysis grades PRNAF stock's Price / Earning ratio at A-. This means that PRNAF stock's Price/Earning ratio is above 9.999999999999998% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this PRNAF may be undervalued for its sector.
The last closing price of PRNAF's stock was USD 0.00.
The most recent market capitalization for PRNAF is USD 0.02B.
Unfortunately we do not have enough analyst data on PRNAF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Alterity Therapeutics Limited's stock.
As per our most recent records Alterity Therapeutics Limited has 10 Employees.
Alterity Therapeutics Limited's registered address is 350 Collins Street, Melbourne, VIC, Australia, 3000.
You can get more information about it from Alterity Therapeutics Limited's website at https://alteritytherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Alterity Therapeutics Limited (PRNAF) Stock
Stock Target Advisor's fundamental analysis for Alterity Therapeutics Limited's stock is Slightly Bearish.
Unfortunately we do not have enough data on PRNAF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PRNAF's stock to indicate what its average analyst target is.
PRNAF stock's Price/Earning ratio is 0.10.
Our analysis grades PRNAF stock's Price / Earning ratio at A-. This means that PRNAF stock's Price/Earning ratio is above 9.999999999999998% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this PRNAF may be undervalued for its sector.
The last closing price of PRNAF's stock was USD 0.00.
The most recent market capitalization for PRNAF is USD 0.02B.
Unfortunately we do not have enough analyst data on PRNAF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Alterity Therapeutics Limited's stock.
As per our most recent records Alterity Therapeutics Limited has 10 Employees.
Alterity Therapeutics Limited's registered address is 350 Collins Street, Melbourne, VIC, Australia, 3000.
You can get more information about it from Alterity Therapeutics Limited's website at https://alteritytherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PRNAF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Join over half-million smart investors across the world
Loading...
The Adjusted Closing and Unadjusted Closing sections display stock prices with and without adjustments, respectively. The Share Trading Volume section shows the stocks trading volume over time, indicating market activity. The Compare Performance section allows you to analyze a stocks performance against others by entering symbols and clicking Add to see relative returns. These tools aid in making informed investment decisions. Use the date range selectors to view trends from the past month (1m), three months (3m), six months (6m), year-to-date (YTD), one year (1y), five years (5y), or all available data (All).
